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Abstract 
 
The production of salt or co-crystalline forms is a common approach to altering the physicochemical 
properties of pharmaceutical compounds. The goal of this work was to evaluate the impact of anion 
choice (succinate, adipate and sulfate) on the physicochemical characteristics of salbutamol forms. 
Novel crystals of salbutamol were produced by solvent evaporation: a co-crystal of salbutamol hemi-
adipate with adipic acid (SA), salbutamol hemi-succinate tetramethanolate (SSU.MeOH) and its 
desolvated form (SSU). The crystalline materials obtained were characterized using: thermal, X-ray, 
NMR, FTIR, DVS and elemental analyses. The crystal forms of SA and SSU.MeOH were determined to 
be triclinic, Pī, and monoclinic, P21/n, respectively. DVS analysis confirmed that SSU and SA do not 
undergo hydration under increased %RH. Thermal and elemental analyses confirmed the stoichiometry 
of the salt forms. The aqueous solubilities of SA and SSU were measured to be 82±2 mg/ml (pH 
4.5±0.1) and 334±13 mg/ml (pH 6.6±0.1), respectively. Measured values corresponded well with 
calculated pH solubility profiles. The intrinsic dissolution rate of co-crystallized SA was approximately 
four times lower than SSU, suggesting its use as an alternative to more rapidly dissolving salbutamol 
sulfate. 
 
 
Keywords: co-crystals, crystal structure, desolvation, dissolution rate, solubility, solvate, thermal 
analysis, water sorption, X-ray powder diffraction. 
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Introduction 
 
 Salbutamol is a β2-mimetic used as a bronchodilator which is presented as the (±) racemic 
mixture in pharmaceutical inhalers (propellant-based and dry powder), nebules, injections, syrups and 
tablets, including controlled-release forms
1
. The hemisulfate salt (commonly referred to as salbutamol 
sulfate) is the most common form of salbutamol used in pharmaceutical products however the (R) 
salbutamol hydrochloride form is also available on the market as an inhalation solution (Xopenex
TM
, 
manufactured by Sepracor Inc.). Although some other salbutamol salts have been reported in the 
literature, e.g. ethanolated salbutamol adipate and salbutamol stearate
2
, to date only two crystal 
structures are reported in the Cambridge Structural Database: salbutamol base (SB)
3
 and salbutamol 
sulfate (SS)
4
. The information about the solid state nature of other forms of salbutamol is sparse.  
From a pharmaceutical point of view, different solid-state characteristics of salt forms can result 
in different in vitro solubility and dissolution properties, which in turn can result in an alteration of the 
in vivo activity of the active pharmaceutical ingredient (API). In particular, for pulmonary delivery, 
possibilities for modification of the dissolution profile of the API from a formulation point of view are 
limited, due to restrictions in terms of the excipients that are regarded as safe for pulmonary use, and 
may result in additional costs and regulatory obstacles associated with the development of a new drug 
product. This may be avoided by the direct production of alternative crystalline forms of the API with 
the desired solubility and dissolution profiles. The marketed solid dosage forms contain only SS, which 
is freely soluble in water
5
. The advantage of prolonged release tablets containing SS was reported in 
clinical studies
6
. New prolonged release oral dosage forms containing SS include hard capsules 
VentMax
TM 
and tablet forms: Volmax CR
TM
, Vospire ER
TM 7
. Both, prolonged release capsules and 
tablets containing SS have monographs in the British Pharmacopeia
8
. A transdermal delivery patch of 
SS was also developed 
9
.   
In this study we investigated the impact of replacing the sulfate anion in the SS salt structure by 
an organic dicarboxylic acid, either the four-carbon chain, succinic (butanedioic) acid or the six-carbon 
 3 
chain, adipic (hexanedioic) acid, on the physicochemical characteristics of the API. These two organic 
acids were chosen in order to investigate the impact of small changes in the chemical structure of the co-
former on the physicochemical properties of the resulting salbutamol forms. A reasonable correlation 
between the melting points of organic co-formers and melting points of the resulting salts was 
previously reported for diclofenac
10
. The authors also observed a trend between the salt melting point 
and the logarithm of the solubility. The reported melting points of adipic and succinic acids are ~151-
154 ˚C and ~185-187 ˚C, respectively11, hence it may be hypothesized that the succinate would have a 
lower solubility than that of the adipate. On the other hand, increasing the hydrophilicity of the 
counterion as a means of increasing the water solubility of the resultant salt has been proposed and 
investigated for a series of erythromycin
12
. The calculated logPs of adipic and succinic acid are 0.356 
and -0.655 respectively
13
, indicating that a salt of adipic acid may be less soluble than that of succinic 
acid. The study performed by Lee at al.
14
 successfully investigated the possibility of forming ionic 
(salts) or neutral (co-crystals) complexes of a heterocyclic base (an ErbB2 inhibitor for the treatment of 
cancer) with dicarboxylic acids comprising succinate, malonate and maleate co-formers. The acids 
(adipic and succinic) used in the current study have similar pKa values. The pKa1 and pKa2 for succinic 
acid are 4.21 and 5.64 
11
 and for adipic acid these are 4.44 and 5.44 
11
. As pKas of salbutamol are 9.1 
and 10.4 
15
, it was expected that the new forms of the API would be novel 1:1 salts of salbutamol.  
Both acids are classified by the U.S. Food and Drug Administration as Generally Recognised As Safe 
(GRAS)
16,17
 and listed in the European Pharmacopeia
5
. Adipic acid is currently used to produce salts of 
piperazine (Entacyl
TM
) and spiramycine (Rovamycine
TM
 injectable form)
11
. Succinic acid is used to 
form salts of e.g. benfurodil, bamethan, chloramphenicol, cibenzoline, deanol, doxylamine, ergotamine, 
loxepine, metoprolol, oxaflumazine, sumatriptan and iron (FeII)
11
.  
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Materials 
 
Salbutamol base was obtained from CHEMOS GmbH Germany. Adipic acid was obtained from Sigma-
Aldrich (Germany) and succinic acid from Sigma-Aldrich Chemical Company (USA) both (99%+ 
grade). HPLC grade methanol was obtained from Fischer Scientific UK. Deionized water was obtained 
from a Purite Prestige Analyst HP water purification system. Potassium bromide (KBr, FTIR grade) was 
obtained from Sigma-Aldrich (Ireland). Deuterated dimethyl sulphoxide (DMSO-d6) was obtained from 
Apollo Scientific Limited (UK) and paraffin wax from BDH Laboratory Supplies Poole, England. All 
other chemicals were of analytical grade and used without further purification.  
 
Methods 
 
Crystallization studies 
Attempts were made to crystallize salbutamol with adipic acid and succinic acid by solvent evaporation 
from ethanol, methanol and water. The tested molar ratios of salbutamol to the acid were: 1:2, 1:1 and 
2:1 for each solvent. It was observed that successful crystallization was achieved only for salbutamol 
mixed with adipic acid in the 1:1 molar ratio using methanol or water as the solvent and for salbutamol 
and succinic acid mixed in the 2:1 molar ratio using methanol (details of the procedure are described 
below). Other combinations resulted either in crystallization of one or two of the components separately 
or in the production of a glassy/amorphous material.  
The crystals subsequently used for single crystal X-ray and other analyses were prepared from saturated 
solutions, which were obtained by introducing an excess of raw material into the appropriate solvent at 
ambient conditions and shaking for an hour on a WhirliMixer
®
 (Fisons Scientific Equipment). 10 mL of 
the suspension obtained was filtered through a 0.22 µm membrane filter into a glass vial which was kept 
in a glove box (Clean Sphere CA 100, Safetech Limited) under constant nitrogen flow at room 
temperature (20-23 ˚C). The moisture content in this controlled environment was less than 1% relative 
humidity.  
 5 
Dry nitrogen flow and temperature control were provided to maintain reproducible conditions of solvent 
evaporation. Crystallization of SA from methanol resulted each time in a very rapid nucleation of the 
crystals. Modification of the environmental conditions, including slowing down the evaporation rate of 
methanol and decreasing the temperature, did not retard the crystal growth. Very small crystals with 
crystal defects (inclusions) were not of sufficiently good quality to be analyzed by single crystal X-ray 
analysis. A change of the solvent to water resulted in slow crystal growth and good quality crystals of 
SA, with a PXRD pattern consistent with that obtained for crystals produced from methanol, hence the 
SA crystals obtained from water were later used for single crystal X-ray analysis. 
 
 
Preparation of salbutamol adipate and succinate  
 
A stoichiometric mixture of salbutamol and adipic acid in a 1:1 molar ratio was dissolved in methanol at 
0.05 g/mL concentration of solid at 25 ˚C. Methanol was evaporated under forced air flow at an 
evaporation rate 0.4 g/min (monitored using a balance every 5 min), whilst stirring. The white 
precipitate was filtered close to the end of methanol evaporation. The precipitate was dried for an hour 
under constant air flow at 25 ˚C. The dry powder was subjected to elemental analysis and was 
determined to be salbutamol mono adipate (SA). It was obtained with a 95% yield. 
A stoichiometric mixture of salbutamol and succinic acid in a 2:1 molar ratio was dissolved in methanol 
at 0.05 g/mL concentration of solid at 25 ˚C. Methanol was evaporated under forced air flow at an 
evaporation rate of 0.4 g/min (monitored using a balance every 5 min), whilst stirring. After nucleation 
of the salt, the temperature was dropped to 20 ˚C and the evaporation rate of methanol was kept constant 
(0.4 g/min) until the concentration of solid in methanol reached 0.1 g/mL. The white precipitate was 
filtered and dried at 25 ˚C. Elemental analysis of the white crystalline powder determined it to be 
salbutamol hemi-succinate tetramethanolate (SSU.MeOH).  It was obtained with a 80% yield. Further 
drying of the precipitate under constant air flow at 25 ˚C for 24 hr resulted in formation of the 
desolvated salbutamol hemi-succinate (SSU). 
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Single crystal X-ray diffraction 
X-ray diffraction measurements were made on a Bruker APEX II DUO diffractometer using graphite 
monochromatized MoKa radiation ( = 0.7107 Å) and an Oxford Cryosystems COBRA fitted with a N2 
generator. All calculations were made using the APEX2 software (APEX2 v2009.3-0, Bruker AXS, 
2009; Sheldrick, 2008)
18
 and the diagrams prepared using Mercury
19
.  
CCDC 801059 (SA) and 801060 (SSU.MeOH) contains the supplementary crystallographic data for this 
paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif 
 
Powder X-ray diffraction (PXRD) 
Powder XRD analysis was conducted using a Rigaku Miniflex II Desktop X-ray diffractometer fitted 
with an Ilaskris cooling unit operating at 30 kV and 15 mA. Ni-filtered Cu-K radiation ( = 1.5408 Å) 
was used. Room temperature measurements were recorded for the range 5-40° 2 at a step size of 0.05 
˚/s 20. 
 
Differential scanning calorimetry (DSC) 
DSC experiments were performed using a Mettler Toledo DSC 821
e
 with a refrigerated cooling system, 
LabPlant RP-100. Nitrogen was used as the purge gas. Aluminium sample holders were sealed with a lid 
and pierced to provide three vent holes. Sample volume was sufficient to provide proper contact 
between the powder and the bottom of the pan, and sample weight was ≥5 mg. DSC measurements were 
carried out at a heating/cooling rate of 10 ˚C/min21. The DSC system was controlled by Mettler Toledo 
STAR
e
 software (version 6.10) working on a Windows NT operating system. The unit was calibrated 
with indium and zinc standards. 
 
 
 7 
Thermogravimetric analysis (TGA) 
TGA was performed using a Mettler TG 50 module linked to a Mettler MT5 balance. Samples were 
placed into open aluminium pans (5-12 mg). A heating rate of 10 ˚C/min was implemented in all 
measurements
21
. Analysis was carried out in the furnace under nitrogen purge and monitored by Mettler 
Toledo STAR
e
 software (version 6.10) with a Windows NT operating system. 
 
Solid state Fourier transform infrared spectroscopy (FTIR) 
Infrared spectra were recorded on a Nicolet Magna IR 560 E.S.P. spectrophotometer equipped with 
MCT/A detector, working under Omnic software version 4.1. A spectral range of 650-4000 cm
-1
, 
resolution 2 cm
-1 
and accumulation of 64 scans were used in order to obtain good quality spectra. A KBr 
disk method was used with a 0.5-1% sample loading. KBr disks were prepared by direct compression 
under 8 bar pressure for 1 min
22
. The sample preparation did not affect the spectra, as confirmed with an 
attenuated total reflectance (ATR) spectrometer (data not shown). The Omnic 4.1
TM
 - FTIR spectra 
analysis with baseline auto correction software was used to analyze the data.   
 
Nuclear magnetic resonance (
1
HNMR, 
13
CNMR) 
A Bruker Avance 400 NMR with 4-nucleus (
1
H, 
13
C, 
31
P and 
19
F) probe was used for NMR studies. 
Deuterated DMSO-d6 was used to prepare the samples. Sample concentration was in the range 20-40 
mg/mL. Spectrometer frequency was 400 MHz with an acquisition time of 2 s. The number of scans 
was appropriate to gain good quality spectra. Standard Pulse Sequence supplied by Bruker was used for 
1
H, DEPT-90, DEPT-135, 
13
C and 2-dimensional CH-COSY experiments. The TopSpin 2.1
TM
 software 
was used to evaluate 
1
HNMR and 
13
CNMR results. 
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Elemental analysis 
Elemental analysis was carried out using an Exeter Analytical CE440 CHN analyzer. The molar amount 
of carbon as carbon dioxide, nitrogen, as nitrogen oxide and hydrogen as water, was determined by 
oxidation of the sample (around 10 mg) and thermal conductivity analysis of the gases obtained
23
.  
 
Dynamic vapor sorption (DVS) 
Vapor sorption experiments were performed on a DVS Advantage-1 automated gravimetric vapor 
sorption analyzer (Surface Measurement Systems Ltd., London, UK). The temperature was maintained 
constant at 25.0 ± 0.1 °C. A mass of around 10 mg of powder was loaded into a sample net basket and 
placed in the system. The samples were equilibrated at 0% of relative humidity (RH) until the dry, 
reference mass was recorded. The samples were exposed to the following % of RH profile: 0 to 90% in 
10% steps and the same for desorption. At each stage, the sample mass was equilibrated (dm/dt ≤ 0.002 
mg/min for at least 10 min) before the change of relative humidity. An isotherm was calculated from the 
complete sorption and desorption profile. Amount of water was expressed as a percentage of the 
reference mass. 
 
Specific surface area analysis (TBET) by Brunauer, Emmett, Teller (BET) isotherm 
Samples were dried prior to analysis under nitrogen flow at 50˚C for 12 hours using a Gemini 
SmartPrep (USA) drying station. To determine the bulk specific surface area a Micromeritics Gemini VI 
(USA) surface area analyzer was used. Compressed nitrogen was used as an adsorptive gas. Each 
measurement consisted of six steps, determining the amount of gas adsorbed at 6 relative pressure points 
in the range of 0.05 to 0.3 of relative pressure P/P0 with equilibration time of 10s. Free space was 
determined separately for each sample using helium gas. Saturation pressure Po was determined prior to 
the measurement of each sample. 
 
 
 9 
Particle size 
Measurements of particle size and particle size distributions were obtained using a laser diffraction 
particle sizer Mastersizer 2000 (Malvern Instruments, UK). Particles were dispersed using a Scirocco 
dry feeder instrument with 2 bar pressure. An obscuration rate of 0.5-6% was obtained under a vibration 
feed rate of 50%. 
 
Solubility studies  
Powdered SA, SSU and SB were added in excess (approximately three times the expected saturated 
concentration of salbutamol) directly to 2 ml of water in an Eppendorf vial at 37 ˚C24. Additionally, the 
SA powder was suspended in a NaOH solution to investigate its solubility at a pH value other than that 
measured for the sample in pure water. The Eppendorfs were placed horizontally in a water bath and 
shaken at 100 cpm. Suspensions were filtered through a 0.22 µm membrane filter. The content of 
salbutamol in the saturated solutions was assayed by UV spectrophotometry at 276 nm (Shimadzu UV 
1700 Pharmaspec). SB, SA and SSU aliquots were diluted with water to obtain the appropriate 
concentration range. Samples were withdrawn and analyzed after 10, 11 and 12 hours and as 
equilibrium appeared to be reached after 10 hours, the values were averaged over these three time 
points.  
The content of adipic and succinic acids in SA and SSU aliquots was determined with a high pressure 
liquid chromatography (HPLC). The HPLC system used was a Shimadzu HPLC Class VP series with a 
LC-10AT VP pump, autosampler SIL-10AD VP and SCL-10AVP system controller. The mobile phase 
was filtered through a 0.45 μm membrane filter (Gelman Supor-450, USA) before use. The HPLC 
method used for the analysis of the dicarboxylic acids was modified from Thoma and Ziegler
25
 and 
Kordis-Krapez et al.
26
. The analytical column used was a LiChrosorb RP-10 column (250 mm length, 
internal diameter 4 mm, particle size 10 μm). UV detection was carried out at a wavelength of 210 nm 
and the injection volume was 20 μL.  
 10 
Separation of adipic acid was carried out isocratically at ambient temperatures with a flow rate of 1 
ml/min. The mobile phase consisted of methanol:phosphoric acid solution (pH 2.1) 20:80 (v/v).  
Separation of succinic acid was carried out using a gradient method with a flow rate of 1 ml/min. The 
mobile phase consisted of two eluents: (A) phosphoric acid solution (pH 2.1) and (B) 
methanol:phosphoric acid solution (pH 2.1) 20:80 (v/v). The following gradient was used: a linear 
gradient from 0 to 50% B over 7 min, then a linear gradient from 50 to 100% B over 1 min and this 
composition was maintained for 7 min. Then again a linear gradient from 100 to 0% B over 10 min was 
applied and the final mobile phase composition was continued for a further 5 min. Under these 
conditions the retention times of adipic acid and succinic were:  4.3 and 6.5 min, respectively.  
 
Intrinsic dissolution studies 
Discs of SS, SSU and SA were prepared by compressing 300 mg of the given material in an IR 
hydraulic press (PerkinElmer, UK). The 13 mm diameter discs had a 1.33 cm
2
 top surface area. The 
bottom and side surfaces of the discs were coated with paraffin wax and mounted in the centre of the 
bottom of a standard dissolution vessel
27
. Each dissolution experiment was performed in triplicate, as 
long as the dissolving disc kept a visibly constant surface area. 
Intrinsic dissolution studies were performed with a type 2 dissolution test apparatus (VanKel VK7000 
dissolution test station) equipped with VK650 heater/circulator)
5
. The rotation speed of the paddle was 
set to 100 rpm. 900 mL of deionized, degassed water was used as the dissolution medium, equilibrated 
at 37 ˚C. To sample the dissolution medium a standard dissolution vessel was equipped with a medium 
recirculation system. The dissolution medium was constantly circulating using a LSMatec peristaltic 
pump fitted with a 0.45 µm filter through a 2 mm flow-through UV cuvette placed in a Cecil CE2020 
UV-spectrophotometer set to 276 nm
28
. The rate of medium circulation was set to 25 mL/min and the 
pH of the aqueous medium was monitored using a Thermo Orion 420+ pH-meter.  
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Statistical analysis  
Statistical analysis was carried out using Minitab™ statistical software, version 14 (Minitab Inc, USA). 
Two sample t-tests were carried out at a significance level of 0.05, with a p-value less than 0.05 taken as 
indicating that the observed difference between the means was statistically significant, i.e. rejecting the 
null hypothesis.  
 
Data analysis 
ACD/Chem Sketch
TM
 freeware was used to calculate theoretical element contributions for elemental 
analysis and partial polarizability volumes
29
.  
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Results and discussion  
Single crystal X-ray analysis  
Single crystal analysis of SA and salbutamol succinate SSU.MeOH was undertaken, of which details are 
shown in Table 1. Crystals of SA are centrosymmetric, with both enantiomers present in the lattice. 
Figure 1a presents the atomic labelling in the unit-cell of the adipate system, which has a 1:1 ratio of 
salbutamol base to adipic acid. The adipate exists in the lattice in both protonated [O(5)] and ionized 
[(O(6), O(7)] forms, as shown by the C-O distances: 1.322(2) Å for the protonated form, and C(17)-
O(6): 1.265(1) Å and C(17)-O(7): 1.261(2) Å for the ionized form. In addition, there is some disorder in 
the hydroxyl group on the stereogenic centre, C(8). Further views of the crystal packing are depicted in 
Figure 2 a, b.  
Crystals of SSU.MeOH (Figure 1b) are also centrosymmetric and were determined to be solvated with 
methanol molecules (Figure 2c and 2d). This was subsequently confirmed by DSC, TGA, elemental 
analysis and 
1
H NMR spectroscopy. The succinate was found in its ionized form, with C-O bond 
distances of 1.274(1) Å and 1.253(2) Å. The SSU.MeOH stoichiometry was 2:1:4.  
 
Analysis of hydrogen bond network 
Analysis of the hydrogen bonds in SA (Table 2) reveals that the vast majority of these bonds occur 
between the hydroxyl groups on the salbutamol and the ionized adipic carboxylate. This carboxylate is 
also hydrogen bonded to the secondary amine group of salbutamol. The protonated adipic acid does not 
play a crucial role in the creation of the hydrogen bond network, with only one hydrogen bond to a 
hydroxyl group of the salbutamol molecule.  
Interestingly, analysis of the hydrogen bonds in methanolated salbutamol succinate (Table 3) reveals the 
crucial role of the methanol in the formation of the lattice and no significant interaction with the ionized 
succinate. Two molecules of methanol are hydrogen bonded together. There is an O-H...O interaction 
with the hydroxyl group of salbutamol, as well as O-H...O hydrogen bonding between the methanol 
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hydroxyl group and salbutamol. In addition, the carboxylate of the succinate interacts with the 
secondary amine and a hydroxyl group of salbutamol.  
A comparison of the crystal packing of SSA (Fig. 2a,b) with SSU.MeOH (Fig. 2c,d) indicates why SSA 
contains an “additional” protonated molecule of adipic acid. It can be seen that SSA molecules packing 
along the c axis (Fig. 2b) consists of channels made of salbutamol molecules. These channels are placed 
centrally around the molecules of adipic acid. The adipic acid molecules are placed one below the other, 
alternating ionized with protonated molecules in each layer. The ionized carboxylic groups of adipic 
acid face towards the secondary amine moieties of salbutamol molecules, while protonated groups are 
placed in close proximity to methoxyls of the benzene ring of salbutamol molecules. This indicates that 
the ionized acid stabilizes more polar parts of the salbutamol molecule, where partial polarizability of R-
NH-Me-MeOH molecule fragment was calculated to be α: 15.68±0.5 Å3 while the protonated molecule 
is responsible for interaction with less polar parts of salbutamol, where partial polarizability of HOMe-
Ar part was calculated to be: α 12.96±0.5 Å3. The interaction is promoted by the close proximity of 
carboxylic acid groups to the channels formed by salbutamol molecules. This is due to the similar length 
of adipic acid to the length of the between-salbutamol channel, i.e. approximately 8 Å -O(5)-O(5) 
distance.  
Succinic acid is much shorter than adipic acid, the O(5)-O(4) distance is approximately 5 Å, and forms a 
different arrangement to SSA along the c axis. Despite the fact that the pKa(s)1,2 of succinic acid (4.21 
and 5.64 at 25 ˚C)11 and adipic acid (4.44 and 5.44 at 25 ˚C)11 are only slightly different, this difference 
seems to be large enough to allow ionized succinic acid to stabilize the amine group and neighboring 
hydroxyl of salbutamol simultaneously. In SSU.MeOH each salbutamol molecule is stabilized, as 
described, by a succinic acid from the one side and a second molecule of salbutamol, in that the amine 
group of SB(A) interacts with the hydroxyl next to the amine group of SB(B). The solvated nature of 
SSU.MeOH arises from the interaction of H-bond dimers (as later described in hydrogen bond network 
analysis) of methanol with hydroxyls of salbutamol.  
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Haynes and co-workers presented a review reporting the occurrence of pharmaceutically acceptable 
anions and cations in the Cambridge Structural Database (CSD)
30
. No examples of a co-crystal of a salt 
of adipic acid were reported and only 23 co-crystalline forms of adipic acid were found. The same 
report indicated the occurrence of only 9 salts of succinic acid indicating that both forms of salbutamol 
presented here are rare in terms of their solid state structures. The SA reported in the current work 
should be classified as a co-crystal of the salbutamol hemiadipate salt with adipic acid in contrast to the 
previously reported ethanolated salt of salbutamol hemiadipate
2
.  
Previously, a co-crystal of the salt of the API with an unionized counterion was reported for the 
anticonvulsant drug valproic acid, where the API comprised co-crystalline form of sodium valproate salt 
with valproic acid
31
. The use of co-crystals in a similar manner to salts in order to alter the 
physicochemical properties of API has been comprehensively investigated 
32-38
, though only one paper 
published so far reports on the co-existence of dianions and an unionized form of the acid in the same 
crystal lattice, similarly to what we have determined for SA, it was a hydrated crystal of escitalopram 
oxalate with oxalic acid
39
. 
 
Hirshfeld surfaces analysis 
Hirshfeld surfaces analysis (Fig. 3) allowed for visualization and comparison of reciprocal interactions 
among atoms in crystal lattices of salbutamol base and salbutamol sulfate compared to salbutamol 
adipate and succinate. The visualization is based on a 3-D surface surrounding a single molecule of 
salbutamol.  
Noticeably, the same chemical structure of salbutamol may present different intensity of reciprocal 
interactions externally and internally to the Hirshfeld surface. Red places named “hot spots”, indicate 
areas of salbutamol molecules where the interactions are the strongest and the distance between 
attracting atoms is shorter than in the case of attraction caused by Van der Waals forces (corresponding 
to white colour on Hirshfeld surface). In all of the derivatives of salbutamol, the most involved areas in 
the formation of hot spots include hydroxyl groups, where hydrogens and oxygens generate separate, 
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independent crystallographically hot spots and the secondary amine group. Hirshfeld surface analysis 
also confirmed that hydrogens of methyl groups of the butyl moiety, secondary methyl group and 
hydrogens of the benzene ring are able to form weak hot spot interactions. It is evident that the molecule 
of salbutamol in the crystal structure of SB forms an intensive hot spot interactions close to O(1)–H(1), 
the same as in co-crystalline form of SA, while this interaction is visibly weaker for  salbutamol 
molecules forming crystal structures of salt forms SS and SSU.MeOH. The intensity of hot spot 
interaction also differs in the case of the methoxyl group O(3)–H(3) attached to the benzene ring of 
salbutamol. Involvement in the strongest (the most intense red color) interaction was for O(3) of SB, a 
slightly weaker interaction was demonstrated by H(3) in crystal structures of SA and SSU.MeOH, while 
O(3) contact lost its intensity. The SS structure presented two weak hot spots, one from the oxygen and 
the other from hydrogen atom. The weakest intensity and distribution on Hirshfeld surface of hot spot 
interactions was for salbutamol base and its co-crystalline form. The hot spot interactions identified 
corresponded well with detected H-bond interactions for SA and SSU listed in tables 3 and 4.   
 
Results of PXRD analysis  
The theoretical powder pattern of SA generated from the single crystal X-ray analysis at 100 K (Figure 
4 a) is consistent with the powder XRD pattern of the bulk material determined at ambient conditions 
(Figure 4 b). There are small differences between the two patterns, which most likely can be attributed 
to thermal anisotropic expansion of the lattice. 
The bulk material consisted of colorless, transparent, rhomboidal, thin, plate-like crystals.  
Results of PXRD analysis of SSU.MeOH (Fig. 5 b) are also consistent with the theoretical PXRD 
pattern (Fig. 5 a). Again, small differences between the two patterns can be attributed to the different 
temperatures used for the experiments. Figure 8 c presents the PXRD pattern of desolvated SSU. 
Broadening and lower intensity of the Bragg peaks may be indicative of damage to the crystal lattice.   
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NMR results  
Table 4 compares 
1
H NMR data recorded for SB and the following salts: SS, SA, SSU.MeOH and SSU. 
Results obtained for SB are consistent with data previously reported by Regla at al. (1997)
40
.  
1
H NMR confirmed the presence of methanol in the crystal structure due to the methyl group (3.18 
ppm), which was absent in the desolvated form. Slight shifts in peak positions between SB and 
salbutamol salt forms may be ascribed to interactions of molecules of dissolved APIs with DMSO.  
Results of 
13
C NMR analysis are listed in Table 5. The number and position of the carbon peaks 
correlate well with data reported by Regla at al. (1997)
40
 for SB. The carbons of adipic acid appeared as 
three peaks corresponding to 6 symmetrical carbons and the carbons of succinic acid showed as two 
peaks corresponding to 4 symmetrical carbons. The 
13
C NMR also detected the carbons (17,16) of 
methanol in the solvated form of SSU.MeOH and their absence in the desolvated form (SSU). 
 
Stoichiometry and elemental analysis  
Elemental analysis confirms the molar ratio of salbutamol and adipic acid in SA is 1:1 (Table 6).  
Elemental analysis of SSU.MeOH correlates well with single crystal X-ray analysis data suggesting a 
ratio of two molecules of salbutamol to one molecule of succinic acid to four molecules of methanol, the 
presence of which in the crystallized material was confirmed by NMR analysis. Results for the solvated 
material have greater variation due to solvate instability at ambient conditions and methanol 
evaporation. Results of elemental analysis confirm that the molar ratio of salbutamol to succinic acid in 
SSU is 2:1. 
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Thermal analysis  
 
Thermal analysis (TGA) of SA did not indicate a significant mass loss on drying at the beginning of the 
scan. Overall mass loss recorded during the TGA scan (Fig. 6 a) up to 100 ˚C was 0.94±0.03% of initial 
mass of the sample. DSC analysis of the material showed a single strong endothermal event (Fig. 6 d) 
related to melting with decomposition at 181.00±0.04 ˚C, correlating with the beginning of significant 
further mass loss in the TGA. The melting point of adipic was measured to be at 150.93±0.10 ˚C. 
DSC analysis of SSU.MeOH (Fig. 6 e) indicated a large broad endotherm with an onset at 69.97±0.30 
˚C and enthalpy of 139.43 J/g. These endothermal events correlated well with the sample mass loss due 
to liberation of methanol (Fig. 6 b) of 17.26±1.20 %. The theoretical content of solvated methanol was 
calculated to be 17.68%.  
The onset of thermal decomposition after desolvation was recorded to be 179.23±0.10 ˚C and 
corresponded with further significant mass loss. In contrast, succinic acid melted at 185.90±0.21 ˚C. 
There was a 0.80±0.02 % overall mass loss up to 100˚C in the TGA determined for SSU (Fig. 6 c, f) 
indicating very slight drying. Onset of thermal decomposition was recorded at 182.83±0.15 ˚C.  
The onsets of thermal decomposition of the new salbutamol forms were consistent with the onset of 
decomposition of about 180 
o
C
41
 for SS. Thus it can be concluded that the new forms and SS have 
similar thermal stability.  
 
FT-IR analysis  
 
The FTIR patterns of SA (Fig. 7 c) and SSU (Fig. 8 d) differ in comparison to spectra of the parent 
compounds (Fig. 7 a, b, e). The main difference between SSA, SSU and SB is the strong suppression of 
conjugated C=C stretching vibrations of benzene ring of salbutamol just above 1600 cm
-1
 and changes 
in the intensity of the carboxylic acid C=O stretch peaks. The stretching vibration of N-H band of 
salbutamol (Fig. 7 e) recorded at 3300 cm
-1
 for SB was nearly completely suppressed and slightly 
shifted towards longer wavelengths in SSU (Fig. 7 d) indicating a complete ionization of the secondary 
amine group. In contrast, the N-H stretching vibration of the secondary amine group in SA (Fig. 7 c) is 
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relatively noticeable with a strong shift to 3450 cm
-1
. These observations agree with the single crystal 
X-ray data suggesting a co-crystal form of SA, where one out of two adipic acid molecules per two 
molecules of salbutamol base remains unionized, but strongly H-bonded to the secondary amine group 
of salbutamol. The co-crystal versus salt forms of salbutamol are clearly distinguishable by FTIR, where 
the broad stretching vibration of C=O of the acid in SSU has been completely suppressed, while the 
acidic carbonyl group vibration in SA remained highly visible with a slight shift towards longer 
wavelengths.     
 
Dynamic Vapor Sorption (DVS)  
 
Both SSU and SA do not adsorb more than 2% of moisture and under the conditions of dynamic vapor 
sorption analysis do not tend to form hydrates (Fig. 8). Results of equilibration of SSU at any given 
RH%, regardless of whether assessed in the sorption or desorption stage,  are similar to SS, and in both 
cases the amount of adsorbed liquid does not exceed 0.3% of initial sample mass at 90% RH. In the case 
of SA sample less than 1.6% of initial mass was adsorbed at 90% RH.  
Since the moisture sorption behavior may be attributed to the powder surface area, the samples 
subjected to the DVS analysis were also characterized in terms of their specific surface area and particle 
size. The specific surface area (TBET) of SS was measured to be 1.53±0.02 m
2
/g, that of SA was 
1.81±0.02 m
2
/g and TBET of SSU was 2.26±0.06 m
2
/g. The median particle size determined was 
8.09±0.18, 19.26±0.07 and 8.73±0.09 µm for SS, SA and SSU, respectively. It is possible, therefore, 
that the higher propensity of SA to sorb moisture may be due to the different particle size, but cannot be 
explained by the difference in the surface area. It is likely that other surface properties, such as surface 
energy, contribute to this effect and will be the subject of further studies.  
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Solubility and dissolution studies 
 
The estimated aqueous solubilities of SA, SSU and SB were found to be 82±2 mg/ml (equivalent to 
0.231±0.001 M of salbutamol) at pH 4.5±0.1, 334±13 mg/ml (equivalent to 1.183±0.045 M of 
salbutamol) at pH 6.6±0.1 and 2.63±0.09 mg/ml (equivalent to 0.0110±0.0004 M of salbutamol) at pH 
10.0±0.1, respectively. Thus the improvement in solubility, compared to SB, was 21- and 108-fold for 
the drug presented as SA and SSU, respectively, indicating that SSU has a 5-fold greater solubility than 
SA.  
As the new forms of salbutamol are composed of the drug and co-former that are able to ionize in 
solution, it is expected that the pH of the saturated medium may have a profound effect on the solubility 
of the compounds
11
. This was investigated for SA, as it was easier to change the pH for this compound 
due to the lower solubility in comparison to SSU. When the pH of medium was adjusted to 5.3, the 
solubility of SA was measured to be 60±1 mg/ml.  
Equations describing the solubility of gabapentin/3-hydroxybenzoic acid cocrystal,
42
 and carbamazepine 
and itraconazole cocrystals have been reported
43
. These models allow relationships between the pH and 
co-crystal solubility to be predicted knowing only the solubility product constant (Ksp) and acid 
dissociation constants of the cocrystal constituents (pKas). Although the theoretically-derived models 
neglect nonidealities due to complexation and other specific interactions, very good agreements between 
the calculated and experimental values were observed
42,43
. This approach was employed in this work as 
the authors suggest that cocrystal solubility and its pH relationship may be estimated from a single 
measurement
43
. Similar mathematical equations were therefore developed for the new salbutamol forms 
to predict their solubility-pH dependence and estimate the solubility difference in relation to the pure 
drug. The co-formers and the drug have acidic and amphoteric characteristics, respectively, therefore the 
previously reported equations were adapted, taking into consideration that each of the species has two 
pKa values and that the stoichiometry of the succinate form is 2:1.  
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SA has a molar ratio 1:1, hence the equation for equilibrium reaction describing dissociation of the 
cocrystal in solution is as follows: 
solutionsolution AHSAHS 22          Eq.1 
where  S-H2A is the cocrystal/salt in the solid phase, Ssolution and H2Asolution are equilibrium solubilities 
of the drug and acid, respectively, thus 
][
]][[
2
2
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
 , and with S-H2A in the solid phase the Ksp can be presented as: 
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Equilibrium reactions for adipic acid and salbutamol are presented in Eqs. 3 and 4 (for the acid) and 
Eqs. 5 and 6 (for the drug). 
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where [HA
-
], [A
2-
] are concentrations of the monodissociated and fully dissociated acid species and 
[SH
+
], [S
-
] are concentrations of protonated and monobasic salbutamol species.  
Combining the total acid and drug concentrations, the solubility of salbutamol adipate can be expressed 
as (Eq.7): 
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where Scocrystal is cocrystal solubility, Ka1,H2A and K a2,H2A are the first and second dissociation constants 
for the acid and Ka1,S and K a2,S are the first and second dissociation constants for the drug. 
Using a similar approach, the equation for salbutamol succinate, considering the 2:1 stoichiometry, is as 
follows (Eq. 8): 
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The pKsp constants for salbutamol adipate and succinate, calculated using the aqueous solubility values, 
were 6.3 and 8.6, respectively. Substituting in pKa values as follows: pKa1=4.44, pKa2=5.44 for adipic 
acid
11
, pKa1=4.21, pKa2=5.64 for succinic acid
11
 and pKa1=9.1, pKa2=10.4 for salbutamol
17
, the pH-
solubility profiles derived from Eqs. 8 and 9 are presented in Fig. 9. The theoretical models suggest that 
a minimum SA solubility occurs at pH around 5 and that of SSU at pH 7.  
The comparison of intrinsic dissolution rates (IDRs) of salbutamol from SA (4.18 mg/cm
2
/min,  
R
2
 of 0.999) and SSU (14.94 mg/cm
2
/min, R
2
 of 0.997) with that of salbutamol sulfate (15.47 
mg/cm
2
/min, R
2
 of 0.999) (Fig. 10) reveals that the rate of salbutamol release from SA is lower than that 
from SS or SSU. The IDR of salbutamol from SA is ~4 times lower and significantly different (p<0.05) 
than that of the other salt forms, consistent with the ~5-fold difference in salbutamol solubility. There 
was no significant difference (p=0.865) between the IDRs of salbutamol in SS and SSU. Our results for 
the co-crystal of the salbutamol hemiadipate salt with adipic acid (SA) contrasts with that of Jashnani et 
al.
2
 who obtained a salbutamol hemiadipate diethanolate which had an IDR equivalent to SS.   
Interestingly, the difference in the IDR values obtained reflect the different acid solubilities i.e. the 
saturated solubility of succinic acid at 20 ˚C is reported to be 7.7% w/v and that of adipic acid to be 
1.8% w/v
45
, therefore it may be expected that the solubility of salbutamol adipate is lower than that of 
salbutamol succinate.  
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Conclusions 
Despite the chemical similarity of succinic and adipic acids, the solid state properties of their salbutamol 
salts when made by the same methods are significantly different. For the first time we reported the 
involvement of adipic acid molecule in the formation of a co-crystal of a salt. Salbutamol succinate is a 
rare example of the succinate constituting a solvated salt form with API molecule. The intrinsic 
dissolution rate of salbutamol in SSU was around 4-fold greater than that of SA, consistent with the ~5-
fold difference in aqueous solubility of salbutamol in SA and SSU, thus the difference in the intrinsic 
dissolution rates was comparable to the solubility trend. Both materials presented similar thermal 
stability and did not undergo hydration under increasing humidity. The effectiveness of anion choice as 
a modification of in vivo bioavailability of salbutamol needs further investigations, as the concept of 
retarding dissolution of an API by the formation of an appropriate salt/co-crystal is a promising 
approach, which may alleviate some issues associated with formulation of extended release dosage 
forms such as component compatibility and regulatory approval for the use of excipients.    
Results described here show that salt and/or co-crystal formation remains largely unpredictable and 
requires predominantly empirical screening. The arrangement of molecules in the crystal lattice is 
dependent on the geometry of the molecules involved and their potential for forming chemical 
interactions. Even the careful choice of similar counter ions can have a profound effect on the observed 
crystalline lattice and further work in this area is required.  
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Table 1. Crystallographic data for SA and SSU.MeOH. 
 
 SA SSU.MeOH 
Crystal system  triclinic monoclinic 
Space group, Z Pī, 2 P 21/n, 4 
Unit cell dimensions, 
° and Å 
a = 9.733(3)   α = 66.354(5) a = 10.3934(5)  
b = 10.700(3) β = 86.080(6) b = 20.2011(10) β =114.5300(10) 
c = 10.926(3) γ = 67.906(5) c = 10.3962(5) 
Volume, Å
3
 961.2(4) 1985.76(17) 
R1 [I>2(I)], wR2 (all data) 0.038, 0.090 0.039, 0.104 
 
Table 2. Hydrogen bonding in SA. 
 
D-H...A D-H, Å H...A, Å D...A, Å D-H...A, ° 
N1-H1A...O7 0.951(19) 1.845(19) 2.7945(18) 175.6(14) 
N1-H1B...O1B 0.96(2) 2.404(18) 2.808(5) 105.0(12) 
N1-H1B...O6
(a)
 0.96(2) 1.88(2) 2.8353(18) 172.2(16) 
O1A-H1C...O7
(a)
 0.84 1.93 2.7619(19) 169 
O1B-H1D...O6
(a)
 0.84 2.46 2.816(5) 106 
O1B-H1D...O7
(a) 
0.84 1.79 2.609(5) 166 
O2-H2A...O6
(b)
 0.84 1.81 2.6327(17) 165 
O3-H3A...O4 
(a)
 0.84 1.92 2.7437(18) 167 
O5-H5…O3(d) 0.88(3) 1.76(3) 2.6314(18) 172(2) 
C6-H6…O3 0.95 2.50 2.8470(19) 101 
C8-H8B…O2(c) 0.99 2.54 3.457(2) 154 
C16-H16A…O1B(a) 0.99 2.29 3.148(5) 144 
Symmetry codes: (a)1-x, -y, 1-z; (b) 1-x, -y, 2-z; (c) –x, -y, 2-z; (d) 1+x, 1+y, -1+z; 
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Table 3. Hydrogen bonding in SSU.MeOH. 
 
D-H...A D-H, Å H...A, Å D...A, Å D-H...A, ° 
O1-H1…O5(b) 0.84 1.79 2.6297(14) 173 
N1-H1A…O4(b) 0.929(18) 1.852(19) 2.7786(15) 175.0(13) 
N1-H1B…O1(c) 0.912(16) 1.924(17) 2.7953(13) 159.1(17) 
O2-H2A…O7(d) 0.84 1.80 2.6312(16) 171 
O3-H3A…O4(e) 0.84 1.85 2.6721(13) 165 
O6-H6A…O3(g) 0.84 1.84 2.6754(13) 174 
O7-H29…O6(h) 0.84 1.81 2.6523(15) 176 
C2-H2…O5(a) 0.95 2.53 3.4744(14) 177 
C6-H6…O3 0.95 2.56 2.8788(14) 100 
C8-H8A…O2(e) 0.99 2.38 3.3068(15) 155 
C11-H11B…O2(f) 0.98 2.57 3.5145(15) 162 
 
Symmetry codes: (a) 1-x, 2-y, 2-z; (b) 1+x, y, z; (c) 2-x, 2-y, 2-z; (d) x, 1+y, z; (e) 1-x, 2-y, 1-z; (f) 3/2-
x, -1/2+y, 3/2-z; (g) x, -1+y, z; (h) -1/2+x, 1/2-y, 1/2+z 
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Table 4. 
1
H NMR analysis of SB and SS, SA, SSU.MeOH and SSU.  
Peak 
SB 
SB  
(Regla at al. 
1997)
40 
SS SA SSU.MeOH SSU 
ν(F1) 
[ppm] 
Integral ν(F1) [ppm] 
ν(F1) 
[ppm] 
ν(F1) 
[ppm] 
ν(F1) [ppm] 
ν(F1) 
[ppm] 
C(10,11,12) 
H(10,11,12) 
1.02 9.08 1.02 1.22 1.21 1.16 1.16 
C(8)H(8AB) 2.54 2.79 2.55 2.78 2.84 2.74 2.71 
C(7)H(7) 4.40 1.09 4.42 4.69 4.70 4.61 4.59 
C(13)H(13AB) 4.48 1.99 4.47 4.50 4.48 4.59 4.49 
C(2)H(2) 6.69 1.00 6.69 6.75 6.74 6.755 6.75 
C(3)H(3) 6.99 1.02 6.99 7.08 7.07 7.04 7.04 
C(6)H(6) 7.27 1.04 7.27 7.34 7.32 7.31 7.31 
C(15,18) 
H(15,18/AB) 
C(15) 
H(15/AB) 
- - - - 2.11 2.28 2.28 
C(16,19) - - - - 1.49 - - 
C(16) 
H(16/ABC) 
C(17) 
H(29-31) 
- - - - - 3.18 - 
 
Table 5. 
13
C NMR analysis of SB and SS, SA, SSU.MeOH and SSU. 
Peak 
SB 
SB (Regla 
at al. 
1997)
40 
SS SA SSU.MeOH SSU 
ν(F1) [ppm] ν(F1) [ppm] ν(F1) [ppm] ν(F1) [ppm] ν(F1) [ppm] ν(F1) [ppm] 
C(10,11,12) 
H(10-12/ABC) 
28.9 28.74 26.7 26.4 27.4 27.4 
C(9) 49.6 49.8 49.7 49.1 50.1 50.2 
C(8)H(8AB) 50.8 50.7 49.6 49.6 49.98 50.0 
C(13)H(13AB) 58.3 58.3 58.7 58.8 58.73 58.8 
C(7)H(7) 72.4 72.3 70.3 69.9 71.11 71.1 
C(2)H(2) 114.0 114.0 114.6 114.7 114.60 114.6 
C(3)H(3) 124.8 124.9 125.5 125.3 125.40 125.4 
C(6)H(6) 125.0 125.1 125.6 125.5 125.54 125.5 
C(1,4,5) 127.9 127.9 128.6 128.6 128.61 128.6 
C(1,4,5) 134.6 134.5 133.4 133.3 133.79 133.8 
C(1,4,5) 153.1 153.1 153.9 154.0 153.90 153.9 
C(14,17) - - - 176.7 176.18 176.2 
C(15,18) - - - 35.9 32.92 32.9 
C(16,19) - - - 25.6 - - 
C(17,16) - - - - 49.06 - 
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Table 6. Comparison of theoretical values and experimental results of elemental analysis of carbon, 
nitrogen and hydrogen contents in salbutamol salts. 
 
Content (%w/w) C % H % N % 
SA 
Theory 1:1  59.20 8.11 3.63 
Experimental 59.00±0.01 8.20±0.08 3.68±0.07 
SSU.MeOH 
Theory 56.34 8.90 3.86 
Experimental 56.53±0.37 8.19±0.18 3.59±0.53 
SSU 
Theory 2:1 60.38 8.11 4.69 
Experimental 60.275±0.05 8.01±0.07 4.61±0.01 
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Fig. 1. a) SA and b) SSU.MeOH showing the atomic labelling. The solvent molecules in SSU.MeOH 
are omitted for clarity. Probability ellipsoids are shown at the 50% level. 
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Fig. 2. a) unit cell of SA, b) extended packing diagram of SA along c axis, c) unit cell of SSU.MeOH, d) 
extended packing diagram of SSU.MeOH along b axis. 
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Fig. 3. Hirschfield surfaces of: a) SB, b) SS, c) SA and d) SSU. 
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Fig. 4. Comparison of SA PXRD patterns: a) theoretical pattern, b) experimental diffractogram. 
 
Fig. 5. Comparison of PXRD patterns: a) SSU.MeOH theoretical pattern, b) SSU.MeOH experimental 
diffractogram and c) SSU experimental diffractogram. 
 
 
Fig. 6. Thermal analysis: a) TGA scan of SA, b) TGA scan of SSU.MeOH, c) TGA scan of SSU, d) 
DSC of SA, e) DSC scan of SSU.MeOH, f) DSC scan of SSU.   
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Fig. 7. FTIR spectra of: a) adipic acid, b) succinic acid, c) SA, d) SSU, e) SB. 
 
 
Fig. 8. Dynamic Vapor Sorption of: SA (squares), b) SSU (triangles), c) SS (diamonds).   
 
 
 
Fig. 9. Theoretical profiles describing pH-solubility dependence for SA (dashed line), SSU (dotted line) 
and SB (solid line). Empty squares indicate experimental solubility values for SA, the triangle for SSU 
and the circle shows the experimental solubility of SB. The inset shows a correlation (y=x) between the 
experimental and predicted data points. 
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Fig. 10. Intrinsic dissolution profiles of SA (diamonds) and SSU (squares) and SS (triangles). 
 
 
 
 
